Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function.
暂无分享,去创建一个
[1] L. Allen,et al. Measurement of total vitamin B12 and holotranscobalamin, singly and in combination, in screening for metabolic vitamin B12 deficiency. , 2006, Clinical chemistry.
[2] Martin Lipkin,et al. The role of vitamin D in cancer prevention. , 2006, American journal of public health.
[3] J. Iwamoto,et al. Amelioration of Osteoporosis and Hypovitaminosis D by Sunlight Exposure in Hospitalized, Elderly Women With Alzheimer's Disease: A Randomized Controlled Trial , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] M. Holick,et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. , 2005, The Journal of clinical endocrinology and metabolism.
[5] Bess Dawson-Hughes,et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. , 2005, JAMA.
[6] Takashi Morihara,et al. A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model , 2005, The Journal of Neuroscience.
[7] P. Lips,et al. Estimates of optimal vitamin D status , 2005, Osteoporosis International.
[8] H. Richter,et al. 25-hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D in human cerebrospinal fluid , 1984, Klinische Wochenschrift.
[9] C. Polman,et al. Multiple sclerosis and vitamin D: an update , 2004, European Journal of Clinical Nutrition.
[10] A. Bava,et al. Vitamin B12 and folate depletion in cognition: a review. , 2004, Neurology India.
[11] Bess Dawson-Hughes,et al. Effect of Vitamin D on falls: a meta-analysis. , 2004, JAMA.
[12] M. Holick,et al. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. , 2004, The American journal of clinical nutrition.
[13] A. Wittich,et al. High prevalence of vitamin D insufficiency in healthy elderly people living at home in Argentina , 2004, European Journal of Clinical Nutrition.
[14] J. Honnorat,et al. Redifferentiation Therapy in Brain Tumors: Long-lasting Complete Regression of Glioblastomas and an Anaplastic Astrocytoma Under Long Term 1-alpha-hydroxycholecalciferol , 2004, Journal of Neuro-Oncology.
[15] W. Stumpf,et al. 1,25(OH)2 vitamin D3 sites of action in spinal cord and sensory ganglion , 2004, Anatomy and Embryology.
[16] R. Yolken,et al. Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera , 2003, Schizophrenia Research.
[17] R. Lew,et al. Effects of Vitamin D and Calcium Supplementation on Falls: A Randomized Controlled Trial , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] François Berger,et al. New clues about vitamin D functions in the nervous system , 2002, Trends in Endocrinology & Metabolism.
[19] Elina Hyppönen,et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study , 2001, The Lancet.
[20] B. Hoffer,et al. Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats , 2001, Brain Research.
[21] S. Shimohama,et al. Protective effects of 1α,25-(OH)2D3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture , 2001, Neuropharmacology.
[22] A. Howie,et al. Extrarenal Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase1 , 2001 .
[23] Philip W. Landfield,et al. Vitamin D Hormone Confers Neuroprotection in Parallel with Downregulation of L-Type Calcium Channel Expression in Hippocampal Neurons , 2001, The Journal of Neuroscience.
[24] K. Wikvall,et al. Porcine microsomal vitamin D(3) 25-hydroxylase (CYP2D25). Catalytic properties, tissue distribution, and comparison with human CYP2D6. , 2000, The Journal of biological chemistry.
[25] T. Hayashi,et al. Vitamin D3 attenuates cortical infarction induced by middle cerebral arterial ligation in rats , 2000, Neuropharmacology.
[26] R. Heaney,et al. Vitamin D: How Much Do We Need, and How Much is Too Much? , 2000, Osteoporosis International.
[27] T. Veenstra,et al. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord , 1999, Journal of Chemical Neuroanatomy.
[28] Yoshihiro Sato,et al. High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. , 1998, Bone.
[29] P. Brachet,et al. 1,25‐dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro , 1998 .
[30] R. Bouillon,et al. Vitamin D and regulation of gene expression. , 1998, Current opinion in clinical nutrition and metabolic care.
[31] P. Brachet,et al. Expression of inducible nitric oxide synthase during rat brain inflammation: Regulation by 1,25‐dihydroxyvitamin D3 , 1998, Glia.
[32] W. Miller,et al. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. , 1997, Molecular endocrinology.
[33] P. Brachet,et al. 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. , 1997, Brain research. Molecular brain research.
[34] P. Galan,et al. Prevalence of Vitamin D Insufficiency in an Adult Normal Population , 1997, Osteoporosis International.
[35] P. Brachet,et al. 1,25‐Dihydroxyvitamin D3, an inducer of glial cell line‐derived neurotrophic factor , 1996, Neuroreport.
[36] T. Dawson,et al. NITRIC OXIDE ACTIONS IN NEUROCHEMISTRY , 1996, Neurochemistry International.
[37] P. Brachet,et al. 1,25‐Dihydroxyvitamin D3 regulates NT‐3, NT‐4 but not BDNF mRNA in astrocytes , 1994, Neuroreport.
[38] A. MacKenzie-Graham,et al. The Role of Nitric Oxide in Glial Pathology a , 1994, Annals of the New York Academy of Sciences.
[39] P. Brachet,et al. 1,25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. , 1994, Brain research. Molecular brain research.
[40] P. Brachet,et al. Synthesis of 1,25‐dihydroxyvitamin D3 by rat brain macrophages in vitro , 1994, Journal of neuroscience research.
[41] S. Carswell,et al. Chronic 1,25-dihydroxyvitamin D3-mediated induction of nerve growth factor mRNA and protein in L929 fibroblasts and in adult rat brain , 1994, Brain Research.
[42] P. Brachet,et al. Expression of 25(OH) vitamin D3 24-hydroxylase gene in glial cells. , 1993, Neuroreport.
[43] M. Somerville,et al. Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels. , 1992, Brain research. Molecular brain research.
[44] R. Houlgatte,et al. 1,25‐Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis , 1991, Journal of neuroscience research.
[45] S. Krane,et al. Metabolic Bone Disease and Clinically Related Disorders , 1990 .
[46] K. Haglid,et al. Parvalbumin increases in the caudate putamen of rats with vitamin D hypervitaminosis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[47] M. Haussler,et al. Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. , 1988, Endocrinology.
[48] V. Luine,et al. 1,25-Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. , 1986, Endocrinology.
[49] H. DeLuca,et al. Brain target sites for 1,25-dihydroxyvitamin D3. , 1982, Science.
[50] H. DeLuca,et al. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. , 1979, Science.
[51] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[52] C. Christiansen,et al. “Anticonvulsant Action” of Vitamin D in Epileptic Patients? A Controlled Pilot Study , 1974, British medical journal.
[53] Burton S. Rosner,et al. Neuropharmacology , 1958, Nature.